Clostridium perfringens TpeL belongs to a family of large clostridial cytotoxins that encompasses
Clostridium perfringens type C has been identified as a causative agent of necrotizing enterocolitis associated with diarrhea and dysentery in infant animals (20, 23) . In humans, the bacteria cause necrotic enteritis, which is termed "pig-bel" (20) . Type C strains produce alpha-toxin, beta-toxin, beta2-toxin, and perfringolysin O. Beta-toxin is lethal, cytotoxic, and related to the pathogenicity of C. perfringens type C (20) . Beta2-toxin is also considered important for pathogenicity (22) . Furthermore, many type C isolates produce a newly discovered toxin named TpeL, which is a truncated homologue of Clostridium difficile TcdA and TcdB (1) . TpeL was identified in the culture supernatant of C. perfringens strain CP4 and is thought to be associated with necrotic enteritis (1) .
TpeL is cytotoxic, causing cell rounding (1) . The molecular mass calculated from the deduced amino acid sequence was 191 kDa, and a signal peptide region was not found within the open reading frame (1) . The deduced amino acid sequence exhibited 30 to 39% homology to Clostridium difficile toxins A (TcdA) and B (TcdB), Clostridium sordellii lethal toxin (TcsL), and Clostridium novyi alpha-toxin (TcnA). All of these toxins are called large clostridial toxins (LCTs) (1) . At least four domains, "ABCD," can be distinguished in LCTs. Respectively, they are putatively involved in N-terminal biological activity (A-domain), C-terminal receptor binding (B-domain), autoproteolytic cleavage during toxin-processing (C-domain), and delivery of the A-domain into the cytosol (D-domain) (2) . LCTs bind with their B-domain to the membrane receptor of host cells (2, 24) . After endocytosis, the toxin inserts into the endosome membrane, most likely via the D-domain. Cellular inositolhexaphosphate (InsP 6 ) activates the protease C-domain (7, 18) . This results in cleavage of the toxin and release of the A-domain into the cytosol. In the cytosol, small GTPases are glycosylated and thereby inactivated. The amino acid sequence of TpeL is shorter than that of other LCTs, and the homologous region was located at the N terminus (1) . A DxD motif in LCTs is essential for glycosyltransferase activity, and the amino acid W102 in TcsL is needed for the enzymatic activity (5, 6) . The DXD motif and W102 of TcsL (1) are conserved in TpeL. However, the C-terminal carbohydratebinding sites of LCTs are not (2, 24) , and it is not known how TpeL binds to its receptor. LCTs monoglycosylate the small GTPases TcdA, TcdB, and TcnA glycosylate Rho, Rac, and Cdc42, whereas TcsL modifies Rac, Ras, Ral, and Rap (24) . TcdA, TcdB, and TcsL use UDP-Glc as a donor for glycosylation of small GTPase (2, 24) . In contrast, TcnA N-acetylglucosaminylates small GTPases by using UDP-GlcNAc, indicating that most clostridial toxins utilize UDP-Glc as a cosubstrate with the exception of the TcnA, which uses UDPGlcNAc (21) . Recently, the crystal structure of the catalytic domain of TcdB was solved (19) .
Our understanding of the biological activity of TpeL remains incomplete. Native TpeL is labile and is difficult to purify from the culture supernatant of C. perfringens type C. Furthermore, since the recombinant full-length TpeL was poorly expressed in Escherichia coli, full-length TpeL is not available. To clarify the catalytic activity of TpeL, we prepared a recombinant glycosyltransferase domain, TpeL1-525 (covering amino acids 1 to 525). To transport enzyme domain into cells, we used the streptolysin O (SLO) delivery systems (25) . Here, we demonstrate that among LCTs, TpeL can utilize both UDP-Glc and UDP-GlcNAc as cosubstrates and mainly glycosylates the Ras subfamily. Plasmids encoding GST-RhoA, GST-Rac1, GST-Cdc42, and GST-Ha-Ras were provided by Y. Horiguchi (Osaka University) and plasmids encoding GST-RalA and GST-Rap1B, by M. Matsuda (Kyoto University). A monoclonal anti-TpeL antibody was prepared as previously described (1) . All other chemicals were of the highest grade available from commercial sources.
MATERIALS AND METHODS

Materials
Construction of TpeL1-525. To prepare the catalytic domain of TpeL, we constructed TpeL1-525, from which 1,125 amino acids have been from the C terminus of TpeL (residues 526 to 1,651), by a PCR using the DNA of the C. perfringens type C strain MC18 (1), a forward primer (5Ј-AGGGGATCCATGG GGTTAATGTCAAAAGAA-3Ј) encoding a BamHI site (indicated in boldface), and a reverse primer (5Ј-TCCCTCGAGTTATTTAACTTGATTAAATGTCCA-3Ј) encoding a downstream XhoI restriction site (indicated in boldface). PCR products were digested with BamHI and XhoI and ligated into BamHI-and XhoI-digested pGEX-4T-1 (GE Healthcare) so that the correct reading frame was maintained with the thrombin cleavage site under the glutathione S-transferase (GST) gene (pGEX-TpeL1-525). The construct was checked by sequencing with an ABI Prism dye terminator cycle sequencing ready reaction kit and ABI 310 cycle sequencer (Life Technologies, Carlsbad, CA).
Expression and purification of TpeL1-525. The recombinant TpeL1-525 was expressed as a protein fused with GST in E. coli BL21 as described previously (15) . After growth (at 30°C) and induction (with IPTG [isopropyl-␤-D-thiogalactopyranoside] to 0.5 mM) of a large culture, the cells were centrifuged and disrupted by a sonicator on ice in a short burst. Centrifugation of the lysate and passage of the soluble fraction over a glutathione-Sepharose (GE Healthcare) column yielded the GST-TpeL1-525 fusion protein at ϳ2 mg/liter. The purified GST-TpeL1-525 was cleaved with thrombin, passed through the glutathioneSepharose column, and then subjected to anion-exchange chromatography (Mono-Q HR10/10; GE Healthcare). The protein was eluted with a 0 to 1.0 M NaCl gradient. Fractions containing TpeL1-525 were collected. The purified proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Fig. 1 ). The protein assay was performed by the method of Bradford (4) .
Assay of cytotoxicity. Vero cells were obtained from the Riken Cell Bank (Tsukuba, Japan). They were cultured in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 U of penicillin/ml, 100 g of streptomycin/ml, and 2 mM glutamine (FCS-DMEM). All incubation steps were performed at 37°C in a 5% CO 2 atmosphere. The test for cytotoxicity was done with Vero cells. Cells in 48-well plates were incubated with 0. (25) . The cells were observed for morphological alterations 4 h after inoculation by phase-contrast microscopy. For cytotoxicity assays, the cells (5 ϫ 10 4 ) were inoculated in 96-well plates. Cell viability was determined by using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt conversion assay (Promega, Madison, WI). The absorbance, which is proportional to the number of viable cells, was read at 490 nm by using an enzyme-linked immunosorbent assay (ELISA) plate reader, using the reference wavelength of 630 nm. The cell viability of a toxin group was calculated as the percentage compared to an untreated control, which was calculated by comparing the mean absorbance value of a toxin group to that of an untreated control for three determinations (16) .
Toxin treatment and lysis of cells. Cell cultures of 6-cm dishes were treated with SLO only or SLO plus TpeL1-525 at 37°C for 15 min. After 120 min of resealing, the cells were rinsed with 5 ml of ice-cold phosphate-buffered saline and scraped off in 300 l of lysis buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 2.5 mM MgCl 2 , 40 g of aprotinin/ml, 0.1 mM phenylmethylsulfonyl fluoride, 20 g of leupeptin/ml, 80 g of benzamidine/ml) per dish. The cells were disrupted mechanically by sonication (five times on ice) and then centrifuged for 10 min at 1,000 ϫ g to remove the nuclear fraction and intact cells. The supernatant (1 mg/ml) was used as the cell lysate (8) .
Fractionation of cell lysates. Lysates were centrifuged at 100,000 ϫ g for 1 h to prepare cytosolic and total particulate fractions. The high-speed pellet, which consists of membrane fractions, was washed with lysis buffer and resuspended in the original volume of lysis buffer (8) .
Immunoblotting. Proteins were separated on 12.5% polyacrylamide gels and transferred onto polyvinylidene difluoride membranes (Millipore) for 2 h at 250 mA. This was followed by blocking with Tris-buffered saline containing 5% (wt/vol) bovine serum albumin and 1% Tween 20 (blocking buffer) for 1 h. Blots were incubated for 2 h with the appropriate primary antibody in the blocking buffer, then for 1 h with a horseradish peroxidase-conjugated secondary antibody, and finally with the reagents from an enhanced chemiluminescence analysis kit. The intensity of the bands was quantified with a densitometer (Atto Co., Ltd., Tokyo, Japan).
Preparation of recombinant GTP-binding proteins. RhoA, Cdc42, Rac1, HaRas, RalA, and Rap1B were prepared from their fusion proteins (e.g., RhoA-GST). GST fusion proteins from the E. coli expression vector pGEX-2T were isolated by affinity purification with GST-Sepharose (GE Healthcare). GTPbinding proteins were then cleaved from the GST fusion proteins by thrombin treatment (100 g/ml for 60 min at 22°C). The thrombin was removed by binding to benzamide-Sepharose, and the GTP-binding proteins were concentrated with Centricon (Millipore).
Glycosylation reaction. Recombinant GTP-binding proteins (50 g/ml) or cell lysates were incubated with TpeL1-525 (20 g/ml) or TcdB (10 g/ml) in a buffer containing 30 M UDP-[ 
RESULTS
Cytotoxic effect of TpeL1-525. TpeL was toxic to Vero cells (1) . We tested the cytotoxicity of the recombinant TpeL1-525, a glycosyltransferase domain of TpeL, to Vero cells. TpeL1-525 alone was without any cytotoxic effects (Fig. 2C) . This finding indicates that TpeL induces cytotoxic effects through the binding of its C-terminal region to cell surface receptors. To confirm this, TpeL1-525 was transported into Vero cells using the pore-forming toxin SLO as a delivery system (25) . As shown in Fig. 2B , in the presence of SLO, TpeL1-525 caused the rounding of cells like the native toxin as reported previously (1). TpeL1-525 at 1 to 10 g/ml in the presence of SLO induced cell rounding in a dose-dependent manner (Fig. 2C) . On the other hands, The cells eventually detached from the well. Furthermore, when TpeL1-525 at a concentration of 1 to 10 g/ml was delivered to the cells by SLO, cell viability de- FIG. 1 . SDS-PAGE analysis of purified TpeL1-525. Lanes: 1, molecular mass standards; 2, GST-TpeL1-525 (7.5 g); 3, thrombin-digested GST-TpeL1-525 (7.5 g); 4, purified TpeL1-525 (7.5 g).
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NAGAHAMA ET AL. (9) reported that the recognition of Rac1 by anti-Rac1 (Mab102) is impaired by the glycosylation of Thr-35 in Rac1. The intracellular level of unmodified Rac1 in Vero cells treated with TpeL1-525 in the presence of SLO was determined using anti-Rac1 (Mab102) (Fig. 3) . TpeL1-525 caused a decrease in the cellular level of unmodified Rac1 (Fig. 3A) . In addition, a quantitative densitometric analysis indicated that TpeL1-525 in the range of 1 to 10 g/ml reduced the relative band intensities applying the antibody Rac1 (Mab102) in a dose-dependent manner (Fig. 3B) . We applied an alternative anti-Rac1 (Mab23A8) recognizing glycosylated and unglycosylated Effect of SLO and SLO plus TpeL1-525 on binding of small GTPases to plasma membranes. Vero cells were incubated with SLO (100 ng/ml) alone or in combination with TpeL1-525 (20 g/ml) at 37°C for 10 min. After 120 min of resealing, the lysate (1 mg/ml) was fractionated into cytosolic and membranous fractions. The membranous fractions were subjected to SDS-PAGE and Western blotting with various anti-small GTPase antibodies. For quantitative analysis, small-GTPase signals were quantified densitometrically. Small GTPase level of untreated cells was set to 1. One representative experiment from three is shown.
DISCUSSION
TpeL is the first LCT shown to utilize UDP-GlcNAc and UDP-Glc to modify small GTP-binding proteins. The substrate specificity of TpeL is similar to that of C. sordellii TcsL. TpeL glycosylates Ha-Ras, RalA, Rap1B, and Rac1.
TpeL1-525 in the presence of SLO induced cell rounding and the detachment of cells from the dish. The cytotoxicity was inhibited by the anti-TpeL antibody, and heat-inactivated TpeL1-525 was not cytotoxic. On the other hand, TpeL1-525 by itself did not have the cytotoxic effects. The results indicated that the N-and C-terminal regions of TpeL plays a role in the cytotoxicity and the C-terminal region is responsible for the binding of cells. The morphological alteration of cultured cells induced by TpeL is similar to that caused by TcdB and TcsL (14, 17) . When the cells were treated with TpeL in the presence of SLO, glycosylation of cellular Rac1 was confirmed by Western blotting with the glycosylation-sensitive anti-Rac1 (Mab102) (9) . TpeL and TcsL (24) act on Rac1 and the Ras subfamily but not RhoA. Furthermore, the isomeric TcdB from the variant C. difficile serotype F strain 1470 (TcdBF) that glucosylates Rac1 but not RhoA, has a cytopathic effect (13) . Halabi-Cabezon et al. (10) reported that the glucosylation of Rac1 rather than RhoA correlates with the cytopathic effect of TcdB. It has been reported that Rac1 plays a critical role in the organization of the actin cytoskeleton (3). These results strongly suggest that glycosylation of Rac1 is critical for the cytopathic effect of TpeL.
TpeL uses UDP-Glc and UDP-GlcNAc as sugar donors. All other LCTs use a single UDP-hexose (2). The crystal structure provides evidence that two amino acids in the vicinity of the catalytic cleft are responsible for the specificity (11). TcdA and TcdB, which both use UDP-Glc, have isoleucine and glutamine in the equivalent positions (Ile-383 and Gln-385 in TcdB), whereas TcnL, which uses UDP-GlcNAc, has serine and alanine residues at the respective positions (11) . It has been reported that the bulkier side chains of Ile-383 and Gln-385 in TcdB limit the space of the catalytic cleft for the binding of UDP-GlcNAc and the exchange of these side chains with smaller groups changes the cosubstrate specificity from UDPGlc to UDP-GlcNAc (11) . TpeL has the smaller side chain Ala-383 and the bulkier side chain Gln-385 at the respective positions (1). We speculate that Ala-383 and Gln-385 in TpeL may stabilize the binding of UDP-Glc and UDP-GlcNAc and favor the acceptance of UDP-Glc and UDP-GlcNAc as the cosubstrates.
The sequential glycosylation of Rac1 by TpeL followed by TcdB, and vice versa indicates that both toxins share the same acceptor amino acid in Rac1. The acceptor amino acid of TcdB-glycosylated Rac1 has been determined as Thr-35 (2, 13). TpeL inactivates Rac1 through the glycosylation of Thr-35.
TpeL glycosylated Rac1, as well as the Ras subfamily consisting of Ha-Ras, RalA, and Rap1B, but not RhoA and Cdc42. Important differences in substrate specificity have been detected among the various LCTs. Whereas TcdA, TcdB, and TcnA modify most RhoA, Rac1, and Cdc42 isoforms, TcsL glucosylates Rac1 but not RhoA or Cdc42 (24) . On the other hand, TcsL also modifies the Ras subfamily, including Ras, Rap, and Ral isoforms (24) . Thus, TpeL modifies similar substrates to TcsL. It was reported that Arg-455, Asp-461, Lys-463, and Glu-472 and residues of helix ␣17 (e.g., Glu-449) of TcdB are essential for enzyme-RhoA recognition (12) . Changing the respective amino acid residues in TcsL to those of TcdB reduced glycosylation of Ras by TcsL (12) . Furthermore, the introduction of helix ␣17 of TcdB into TcsL caused a reduction in the glycosylation of Ras subfamily proteins but permitted the glycosylation of RhoA, indicating that helix ␣17 is involved in RhoA's recognition by TcdB (12) . Glu-449, Lys-463, and Glu-472 in TcdB correspond to Lys, Arg, and Gly residues in TcsL and TpeL. Arg-455 in TcdB corresponds to Lys in TcsL and Gly in TpeL (1). The difference in those amino acid residues may be involved in recognizing small GTPases by TpeL. Additional residues in LCTs are needed for the recognition of small GTPases.
In conclusion, TpeL from C. perfringens has been identified as a glycosyltransferase using UDP-GlcNAc and UDP-Glc as cosubstrates. The substrates of TpeL are confined to Rac1 and Ras subfamily proteins. The modification of Thr-35 on Rac1 induces cytopathic effects.
